170 related articles for article (PubMed ID: 23305796)
1. Molecular markers in pancreatic cancer diagnosis.
Herreros-Villanueva M; Gironella M; Castells A; Bujanda L
Clin Chim Acta; 2013 Mar; 418():22-9. PubMed ID: 23305796
[TBL] [Abstract][Full Text] [Related]
2. Biomarkers in pancreatic cancer: diagnostic, prognostic, and predictive.
Fong ZV; Winter JM
Cancer J; 2012; 18(6):530-8. PubMed ID: 23187839
[TBL] [Abstract][Full Text] [Related]
3. Cell-free plasma microRNA in pancreatic ductal adenocarcinoma and disease controls.
Carlsen AL; Joergensen MT; Knudsen S; de Muckadell OB; Heegaard NH
Pancreas; 2013 Oct; 42(7):1107-13. PubMed ID: 24048453
[TBL] [Abstract][Full Text] [Related]
4. Comparison of plasma Tu-M2-PK and CA19-9 in pancreatic cancer.
Joergensen MT; Heegaard NH; Schaffalitzky de Muckadell OB
Pancreas; 2010 Mar; 39(2):243-7. PubMed ID: 19820423
[TBL] [Abstract][Full Text] [Related]
5. Evaluation of serum diagnosis of pancreatic cancer by using surface-enhanced laser desorption/ionization time-of-flight mass spectrometry.
Gao H; Zheng Z; Yue Z; Liu F; Zhou L; Zhao X
Int J Mol Med; 2012 Nov; 30(5):1061-8. PubMed ID: 22941199
[TBL] [Abstract][Full Text] [Related]
6. Serum CA19-9, cathepsin D, and matrix metalloproteinase-7 as a diagnostic panel for pancreatic ductal adenocarcinoma.
Park HD; Kang ES; Kim JW; Lee KT; Lee KH; Park YS; Park JO; Lee J; Heo JS; Choi SH; Choi DW; Kim S; Lee JK; Lee SY
Proteomics; 2012 Dec; 12(23-24):3590-7. PubMed ID: 23065739
[TBL] [Abstract][Full Text] [Related]
7. Towards pancreatic cancer diagnosis using EIS biochips.
Chiriacò MS; Primiceri E; Monteduro AG; Bove A; Leporatti S; Capello M; Ferri-Borgogno S; Rinaldi R; Novelli F; Maruccio G
Lab Chip; 2013 Feb; 13(4):730-4. PubMed ID: 23287869
[TBL] [Abstract][Full Text] [Related]
8. A novel serum metabolomics-based diagnostic approach to pancreatic cancer.
Kobayashi T; Nishiumi S; Ikeda A; Yoshie T; Sakai A; Matsubara A; Izumi Y; Tsumura H; Tsuda M; Nishisaki H; Hayashi N; Kawano S; Fujiwara Y; Minami H; Takenawa T; Azuma T; Yoshida M
Cancer Epidemiol Biomarkers Prev; 2013 Apr; 22(4):571-9. PubMed ID: 23542803
[TBL] [Abstract][Full Text] [Related]
9. Investigational biomarkers for pancreatic adenocarcinoma: where do we stand?
Datta J; Vollmer CM
South Med J; 2014 Apr; 107(4):256-63. PubMed ID: 24937521
[TBL] [Abstract][Full Text] [Related]
10. MicroRNAs as diagnostic markers for pancreatic ductal adenocarcinoma and its precursor, pancreatic intraepithelial neoplasm.
Xue Y; Abou Tayoun AN; Abo KM; Pipas JM; Gordon SR; Gardner TB; Barth RJ; Suriawinata AA; Tsongalis GJ
Cancer Genet; 2013 Jun; 206(6):217-21. PubMed ID: 23933230
[TBL] [Abstract][Full Text] [Related]
11. Identification of human complement factor B as a novel biomarker candidate for pancreatic ductal adenocarcinoma.
Lee MJ; Na K; Jeong SK; Lim JS; Kim SA; Lee MJ; Song SY; Kim H; Hancock WS; Paik YK
J Proteome Res; 2014 Nov; 13(11):4878-88. PubMed ID: 25057901
[TBL] [Abstract][Full Text] [Related]
12. Toward a better understanding of pancreatic ductal adenocarcinoma: glimmers of hope?
Partensky C
Pancreas; 2013 Jul; 42(5):729-39. PubMed ID: 23648843
[TBL] [Abstract][Full Text] [Related]
13. Development of serum parameters panels for the early detection of pancreatic cancer.
Zhang P; Zou M; Wen X; Gu F; Li J; Liu G; Dong J; Deng X; Gao J; Li X; Jia X; Dong Z; Chen L; Wang Y; Tian Y
Int J Cancer; 2014 Jun; 134(11):2646-55. PubMed ID: 24615168
[TBL] [Abstract][Full Text] [Related]
14. Recent advances in proteomically subtyping pancreatic ductal adenocarcinomas and their potential clinical impact.
Roesli C
Expert Rev Proteomics; 2015 Feb; 12(1):5-8. PubMed ID: 25407217
[TBL] [Abstract][Full Text] [Related]
15. Methylation profile of circulating plasma DNA in patients with pancreatic cancer.
Melnikov AA; Scholtens D; Talamonti MS; Bentrem DJ; Levenson VV
J Surg Oncol; 2009 Feb; 99(2):119-22. PubMed ID: 19065635
[TBL] [Abstract][Full Text] [Related]
16. Molecular markers of early pancreatic cancer.
Goggins M
J Clin Oncol; 2005 Jul; 23(20):4524-31. PubMed ID: 16002843
[TBL] [Abstract][Full Text] [Related]
17. An animal model of preclinical diagnosis of pancreatic ductal adenocarcinomas.
Fukamachi K; Tanaka H; Hagiwara Y; Ohara H; Joh T; Iigo M; Alexander DB; Xu J; Long N; Takigahira M; Yanagihara K; Hino O; Saito I; Tsuda H
Biochem Biophys Res Commun; 2009 Dec; 390(3):636-41. PubMed ID: 19818733
[TBL] [Abstract][Full Text] [Related]
18. Major molecular markers in pancreatic ductal adenocarcinoma and their roles in screening, diagnosis, prognosis, and treatment.
Singh P; Srinivasan R; Wig JD
Pancreas; 2011 Jul; 40(5):644-52. PubMed ID: 21673535
[TBL] [Abstract][Full Text] [Related]
19. Development of a miRNA-based diagnostic assay for pancreatic ductal adenocarcinoma.
Szafranska-Schwarzbach AE; Adai AT; Lee LS; Conwell DL; Andruss BF
Expert Rev Mol Diagn; 2011 Apr; 11(3):249-57. PubMed ID: 21463235
[TBL] [Abstract][Full Text] [Related]
20. Clinical significance of cathepsin E in pancreatic juice in the diagnosis of pancreatic ductal adenocarcinoma.
Uno K; Azuma T; Nakajima M; Yasuda K; Hayakumo T; Mukai H; Sakai T; Kawai K
J Gastroenterol Hepatol; 2000 Nov; 15(11):1333-8. PubMed ID: 11129230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]